Referenties

  1. Gecse KB, et al. J Crohns Colitis 2016;10(2):133-40.
  2. Jørgensen KK, et al. Lancet 2017;389:2304-16.
  3. QuintilesIMS. MIDAS, February 2017.
  4. INFLECTRA® Summary of Product Characteristics.
  5. European Public Assessment Report: INFLECTRA®. Available here. Accessed December 2017.
  6. European Medicines Agency. Guidelines on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. Available here. Accessed December 2017.
  7. Yoo DH. Expert Rev Clin Immunol 2017;13(7):653-66.
  8. Danese S, et al. Aliment Pharmacol Ther 2011;33:857-69. 
  9. Moss AC. Gastroenterol Rep 2015;3(1):63-8.
  10. FDA. CBER approval letter, infliximab. 1998. Available here. Accessed December 2017.
  11. EMA. Public Statement on Remicade (infliximab). 2000. Available here. Accessed December 2017.
  12. Medscape. [Public Release: 22 September 2005]. https://www.medscape.com/viewarticle/513282. Accessed December 2017.
  13. EMA. Remicade Scientific Discussion. 2006.
  14. Centocor, Inc. [Public Release: 6 November 2007]. https://www.eurekalert.org/pub_releases/2007-11/ci-rbf110607.php. Accessed December 2017.
  15. Remicade (infliximab). www.remicade.com. Accessed December 2017.
  16. Gomollon F, et al. J Crohns Colitis 2016;1-26.
  17. Dignass A, et al. J Crohns Colitis 2012;6:991-1030.
  18. Danese S, et al. J Crohns Colitis 2017;11:26-34.
  19. Kim YH, et al. Abstract LB04, UEGW 2017. United European Gastroenterol J 2017;5:1139-40.
  20. Fiorino G, et al. Inflamm Bowel Dis 2017;23:233-43.
  21. Abstracts of ECCO 2017. J Crohns Colitis 2017;11/Supp 1 [Alfonso J, et al. P248. Ametzazurra A, et al. P503. Choe YH, et al. P487. Choe YH, et al. P500. Curdia Goncalves T, et al. P472. Eberl A, et al. P639. Fiorino G, et al. P605. Fiorino G, et al. P633. Gompertz M, et al. P679. Gonzalez A, et al. P508. Guerrero Puente LN, et al. P545. Han S, et al. P582. Huoponen S, et al. P685. Juan G, et al. P632. Kang B, et al. P542. Kaniewska M, et al. P425. Kolar M, et al. P532. Lovasz BD, et al. P592. Molnar T, et al. P675. Mortier K, et al. P333. Nugent S, et al. P430. Plevris N, et al. P586. Rodriguez Glez GE, et al. P629. Sladek M, et al. P661. Smits L, et al. P663. Soret PA, et al. P471. Strik A, et al. P665. St. Clair Jones A, et al. P527.].
  22. Abstracts of ECCO 2016. J Crohns Colitis 2016;10/Supp 1 [Bortlik M, et al. P495. Carvalho L, et al. P327; Diaz Hernández L, et al. P449. Guerra Veloz MF, et al. P452; Guerra Veloz MF, et al. P600; Hamanaka S, et al. P329. Kaniewska M, Rydzewska G. P645. Kolar M, et al. DOP032. Muhammed R, et al. P382. Sieczkowska J, et al. P530. Turk N, et al. P577. Zagorowicz E, et al. P513.].
  23. Abstracts of BSG 2016. Gut 2016;7/Supp 1 [Ala K, et al. PTU-059; Bennett KJ, et al. PWE-017; Chung L, et al. OC-038; Rahmany S, et al. PTU-073.].
  24. Farkas K, et al. J Crohns Colitis 2016;10:1273-8.
  25. Hlavaty T, et al. Gastroenterol Hepatol 2016;70:27-32.
  26. Jahnsen J, et al. Expert Rev Gastroenterol Hepatol 2015;9(S1):S45-52.
  27. Keil R, et al. Scand J Gastroenterol 2016;51:1062-8.
  28. UK inflammatory bowel disease (IBD) programme steering group. Royal College of Physicians, UK. IBD Biological Therapy Audit 2016. Available here. Accessed December 2017.
  29. Razanskaite V, et al. J Crohns Colitis 2017 Jan 27 epub.
  30. Smits LJ, et al. J Crohns Colitis 2016;10:1287-93.
  31. ClinicalTrials.gov. NCT02096861. Available here. Accessed December 2017.
  32. Kim YH, et al. Abstract 101, AOCC 2017.
  33. EUDRA CT 2013-004497-10 CT-P13 3.4 trial record. Available here. Accessed December 2017.
  34. Kim YH, et al. Abstract DOP061, ECCO 2017. J Crohns Colitis 2017;11/Supp 1:S62

Gerelateerde indicatiegebieden

PP-IFA-NLD-0096